HABA Laboratories, Inc. AI Stock Analysis
Want to see JP:4925 full AI Analyst Report?
HABA Laboratories, Inc. (4925) AI Stock Analysis
HABA Laboratories, Inc.
(TSE/TYO:4925)
The overall score of 83 is primarily driven by HABA Laboratories' successful financial turnaround, characterized by strong free cash flow and a healthy balance sheet. The stock's attractive valuation and solid bullish technical trends provide further upside support, with flat revenue growth remaining the only notable risk factor.
HABA Laboratories, Inc. (4925) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 6.28B
- Dividend Yield
- 2.41%
- Average Volume (3M)
- 1,956
- Price to Earnings (P/E)
- 10.9
- Beta (1Y)
- 0.29
- Revenue Growth
- -2.92%
- EPS Growth
- -25.96%
- Country
- Japan
- Employees
- 523
- Sector
- General
- Sector Strength
- 55
- Industry
- Household & Personal Products
HABA Laboratories, Inc. Business Overview & Revenue Model
Company Description
Established in Tokyo, Japan, in 1983, HABA Laboratories, Inc. develops and distributes a comprehensive range of skincare, hair, and body care items both domestically and across international markets. Their skincare portfolio encompasses facial cleans...
How the Company Makes Money
null
HABA Laboratories, Inc. Financial Statement Overview
Summary
HABA Laboratories demonstrates a textbook financial turnaround with robust cash flow generation, restored profitability margins, and aggressive debt reduction leading to a pristine balance sheet. The score is only constrained by stagnant top-line revenue growth.
Income Statement
68PositiveBalance Sheet
88Very PositiveCash Flow
82Very Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.04B | 12.14B | 12.06B | 12.32B | 12.04B | 12.91B |
| Gross Profit | 7.96B | 7.95B | 7.99B | 8.03B | 8.17B | 8.79B |
| EBITDA | 802.02M | 898.40M | 811.56M | -1.31B | 17.05M | 448.30M |
| Net Income | 680.57M | 760.36M | 576.57M | -2.12B | -707.87M | -269.03M |
Balance Sheet | ||||||
| Total Assets | 11.66B | 12.52B | 12.34B | 12.43B | 14.73B | 15.76B |
| Cash, Cash Equivalents and Short-Term Investments | 5.15B | 5.78B | 4.74B | 3.96B | 4.82B | 5.65B |
| Total Debt | 959.17M | 1.19B | 1.82B | 2.36B | 2.03B | 2.56B |
| Total Liabilities | 2.31B | 2.98B | 3.42B | 3.92B | 3.96B | 4.12B |
| Stockholders Equity | 9.35B | 9.54B | 8.93B | 8.51B | 10.77B | 11.64B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 1.16B | 1.48B | -1.02B | -232.69M | 1.53B |
| Operating Cash Flow | 0 | 1.24B | 1.62B | -587.92M | 55.96M | 1.71B |
| Investing Cash Flow | 0 | 484.54M | -147.18M | -441.79M | -214.40M | -216.49M |
| Financing Cash Flow | 0 | -780.75M | -689.49M | 171.06M | -676.32M | -1.51B |
HABA Laboratories, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4925, the sentiment is Negative. The current price of 1660.00 is below the 20-day moving average (MA) of 1669.50, below the 50-day MA of 1695.72, and below the 200-day MA of 1717.03, indicating a bearish trend. The MACD of -9.42 indicates Negative momentum. The RSI at 39.10 is Neutral, neither overbought nor oversold. The STOCH value of 56.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4925.
HABA Laboratories, Inc. Peers Comparison
Overall Rating
JP:493383Outperform
JP:492583Outperform
JP:491874Outperform
JP:492665Neutral
JP:492058Neutral
JP:493651Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | JPY 42.77B | 22.54 | ― | 0.92% | 19.48% | -22.87% | |
| 83Outperform | JPY 6.28B | 10.86 | ― | 2.41% | -2.92% | -25.96% | |
| 74Outperform | JPY 2.71B | 13.80 | ― | 3.14% | -5.54% | -55.93% | |
| 65Neutral | JPY 5.32B | 20.91 | ― | 1.61% | 1.51% | -18.54% | |
| 58Neutral | JPY 2.21B | 8.24 | ― | 2.84% | 9.96% | 2053.18% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 51Neutral | JPY 6.77B | -13.82 | ― | 3.56% | -0.08% | -246.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4925 | HABA Laboratories, Inc. | 1660.00 | 33.96 | 2.09% | |
| JP:4918 | Ivy Cosmetics Corporation | 478.00 | 157.28 | 49.04% | |
| JP:4920 | Nippon Shikizai, Inc. | 1055.00 | 8.42 | 0.80% | |
| JP:4926 | C'BON COSMETICS Co., Ltd. | 1243.00 | 61.40 | 5.20% | |
| JP:4933 | I-ne CO., LTD. | 2403.00 | 993.62 | 70.50% | |
| JP:4936 | AXXZIA, Inc. | 281.00 | -130.75 | -31.76% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026
